Clinical Trials
Clinical Trials are research studies where people volunteer to help find answers to health questions. Studies are conducted in a safe, controlled environment and often lead to new treatments.
Clinical Trials are conducted according to a specific plan called a protocol. This document describes who may participate, what tests and procedures will be scheduled, what drugs and dosages will be given, how long the patient will participate, and what researchers hope to learn from the study.
Dr. Brig is pleased to offer Clinical Trial services to his patients. The following studies are currently enrolling at Brig Center for Cancer Care and Survivorship:
BREAST – Neoadjuvant Triple Negative Breast Cancer”
Pfizer, C3441020 (Neo-Tala): A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA 1/2 Mutation Patients with Early Triple-Negative Breast Cancer
BREAST – Advanced ER+/Her2 Negative Breast Cancer”
Radius, RAD1901-308 (Emerald): Elacestrant Monotherapy Vs. Standard of Care for the Treatment of Patients with ER+, HER2 Negative Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial
BREAST – Metastatic Triple Negative Breast Cancer
AstraZeneca, D533600001 (VIOLETTE): A Phase II, Open Label, Randomized, Multi-Center Study to Access the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer
Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2)
Breast – Unresectable or Metastatic HER2 Low
Daiichi Sankyo, DS8201-A-U303 (DESTINY-04) : A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial of DS-8201A, an Anti-HER2-Antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice for HER2Low, Unresectable and/or Metastatic Breast Cancer
Breast – Advanced or Metastatic HER2+
Seattle Genetics, SGNTUC-016: Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
Non-Myeloid Malignancies
Amgen, 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-Myeloid Malignancies at High Risk for FN and Receiving Neulasta Onpro Kit or Other Physician Choice Options for Prophylaxis of FN
If you have any questions or want further information, please contact Kristi Simcox at (865) 246-1958 or 865-415-3329.